Safety of subcutaneous allergen immunotherapy in children: A retrospective review and bird eye to literature

Subcutaneous allergen immunotherapy (SCIT) has been shown to improve clinical course in children with asthma and allergic rhinitis (AR). Systemic and local side-effects may be seen during its administration. The purpose of this study was to evaluate risk factors associated with systemic and local side-effects in children receiving SCIT. We performed a retrospective chart review in the children who received allergen subcutaneous immunotherapy for asthma and/or allergen rhinitis. Demographic data, diagnosis, skin prick test results, presence of additional allergic diseases, the seasonal variation of adverse events in the first and third years of SCIT were recorded. A total of 508 eligible patients were included in the study. Mean age of the children was 10.9±3.2 years, and 65.4% were male. Asthma was present in 21.9% of the children, AR in 44.7%, 33.5% of them had both asthma and AR. According to the skin prick test results, sensitivity to more than one allergen was present in 45.1%, while the most common single-allergen sensitivities were to grass pollen and dermatophagoids (32.5% and 14.4%, respectively). Ratio of systemic and local side-effects was 4.7% and 9.3%, respectively. Local side-effects were more common than systemic reaction. SCIT is a safe treatment modality while using the appropriate dose and with the administration of dose-escalation protocol

Follicular bronchiolitis: a rare disease in children

Foliküler bronşiyolit (FB), benign ilerleyici bir akciğer hastalı- ğıdır. Küçük havayollarında peribronşiyal alanlarda lenfoplaz- moselüler infiltrasyon ve hiperplastik foliküllerle belirgindir. Çocuklarda kronik öksürük, tekrarlayan solunum yolu enfeksi- yonları, ilerleyici dispne olduğu durumlarda foliküler bronşiyo- lit düşünülmelidir. Tanı akciğer biyopsisi ile desteklenmelidir. Sekiz yaşında kız hasta hastanemize devam eden öksürük ve hırıltı yakınmaları ile başvurdu. Akciğerde dinlemekle yaygın iki taraflı ral ve ronküsleri olan hastanın, akciğer grafisinde re- tiküloglandüler görünüm saptandı. Yüksek rezolüsyonlu toraks bilgisayarlı tomografisinde iki taraflı yaygın septal kalınlaşma- lar, retikülonodüler görünüm, yer yer bronşiektazi, bronşiyo- lektazi ve peribronşiyal kalınlaşmalar saptandı. Yapılan akciğer biyopsisinde foliküler bronşiyolit tanısı aldı. Metil prednizolon tedavisinden sonra hastamızın belirtilerinde ve klinik bulgu- larında gerileme gözlendi. Bu olgu kronik bronşiyal obstrük- siyon kliniği ile başvuran ve standart tedavilere yanıtsız ço- cuklarda, nadir görülen interstisyel akciğer hastalıklarının da düşünülmesi gerektiğini vurgulamak amacı ile sunulmuştur. (Türk Ped Arş 2014; 49: 344-7)Follicular bronchiolitis (FB) is a benign progressive lung di- sease. It is characterized with lymphoplasmocellular infiltra- tion and hyperplastic follicles in the peribronchial areas in the small airways. Follicular bronchiolitis should be conside- red in cases where chronic cough, recurrent upper respira- tory tract infections and progressive dyspnea are observed in children. The diagnosis should be supported by lung biopsy. A 8-year old female patient presented to our hospital with complaints including continuing cough and wheezing. Bila- teral extensive rales and rhonchi in the lungs were heard on auscultation and lung graphy revealed reticuloglandular ap- pearance. Bilateral extensive septal thickennings, reticulono- dular appearance, patchy bronchiectasis, bronchiolectasis and peribronchial thickennings were found on high-resolution thoracal computarized tomography. A diagnosis of follicular bronchiolitis was made as a result of lung biopsy. Improve- ment was observed in the complaints and findings of our patient after methylprednisolone treatment. This patient was presented to emphasize rare interstitial lung diseases should also be considered in children who present with a clinical pic- ture of chronic bronchial obstruction and do not respond to standard treatment. (Türk Ped Arş 2014; 49: 344-7

Safety of subcutaneous allergen immunotherapy in children: A retrospective review and bird eye to literature

Subcutaneous allergen immunotherapy (SCIT) has been shown to improve clinical course in children with asthma and allergic rhinitis (AR). Systemic and local side-effects may be seen during its administration. The purpose of this study was to evaluate risk factors associated with systemic and local side-effects in children receiving SCIT. We performed a retrospective chart review in the children who received allergen subcutaneous immunotherapy for asthma and/or allergen rhinitis. Demographic data, diagnosis, skin prick test results, presence of additional allergic diseases, the seasonal variation of adverse events in the first and third years of SCIT were recorded. A total of 508 eligible patients were included in the study. Mean age of the children was 10.9 +/- 3.2 years, and 65.4% were male. Asthma was present in 21.9% of the children, AR in 44.7%, 33.5% of them had both asthma and AR. According to the skin prick test results, sensitivity to more than one allergen was present in 45.1%, while the most common single-allergen sensitivities were to grass pollen and dermatophagoids (32.5% and 14.4%, respectively). Ratio of systemic and local side-effects was 4.7% and 9.3%, respectively. Local side-effects were more common than systemic reaction. SCIT is a safe treatment modality while using the appropriate dose and with the administration of dose-escalation protocol